Novo Nordisk A/S Stock News

Healthcare stocks can be excellent choices for investors, offering a balance of safety and growth. Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk all have strong growth potential.

Mish Schneider discusses her stock and ETF picks as stocks continue to tick lower today. She highlights Novo Nordisk (NVO), E.L.F. Beauty (ELF), and Invesco Solar ETF (TAN). Tune in to find out more a

A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.

In the latest trading session, Novo Nordisk (NVO) closed at $123.46, marking a -0.36% move from the previous day.

The future of the U.S. economy appears promising, with robust growth and strong corporate performance. This economic strength has propelled the stock market to record highs, signaling confidence in th

A staggering $1 trillion could be the annual cost to the US healthcare system if 40% of Americans with obesity begin treatment with GLP-1 drugs at current prices, according to Dr Jonathan Gruber, th

Ozempic usage for weight loss has gone viral, making it the highest revenue-generating drug for Novo Nordisk AV/S NYSE: NVO. Originally purposed for Type 2 diabetes, the skyrocketing off-label use for

Nvidia, which bucked the S&P 500 downdraft last week, leads this weekend's watch list of five stocks near buy points.

BMO Capital Markets initiated coverage on Danish drug maker Novo Nordisk A/S NVO after the company garnered interest as it hit the holy grail with the next generation of famed weight loss and diabe

The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's Zepbound and Mounjaro.

Novo Nordisk and Eli Lilly & Co., the dynamic duo of the weight-loss drug world, still have plenty of upside even after their shares have surged over the past 12 months, BMO Capital Markets analysts s

A committee of the European Medicines Agency said Friday that a popular weight-loss drug doesn't increase the risk of suicide.

Weight-loss stocks remain the focus of many investors. The GLP-1 drugs that many companies have put forward address key health concerns like obesity and diabetes, which have become epidemics in many W

If you're wondering which stocks to buy in April, here's a good place to start. The stock market is off to a difficult start in the second quarter.

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.